Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 5,507 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

NCT00942240
View directory record Official record
Conditions
Healthy
Interventions
ACU-4429, matching placebo tablet
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

NCT02185040
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
35
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

NCT00576589
View directory record Official record
Conditions
Obesity
Interventions
CE-326,597, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2010 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Not applicable Interventional Results available

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil

NCT01317550
View directory record Official record
Conditions
Lung Cancer
Interventions
Armodafinil, Placebo, Minocycline, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

NCT01188317
View directory record Official record
Conditions
Healthy Volunteer
Interventions
aleglitazar, placebo, ibuprofen
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 28, 2026, 6:31 PM EDT
Terminated Phase 2 Interventional Results available

Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00019747
View directory record Official record
Conditions
Colorectal Cancer
Interventions
thalidomide, adjuvant therapy, Placebo
Drug · Procedure · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
6
States / cities
Goshen, Indiana • Bethesda, Maryland • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Non-Anemic Iron Deficiency in Pregnancy

NCT05423249
View directory record Official record
Conditions
Non-anemic Iron Deficiency
Interventions
Ferrous sulfate, Prenatal, Docusate Sodium, Ascorbic Acid 500Mg Tab, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Bohemia, New York • Commack, New York • East Setauket, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Early Phase 1 Interventional Results available

Melatonin Versus Placebo in Breast Cancer

NCT01805089
View directory record Official record
Conditions
Breast Cancer
Interventions
Melatonin 3 mg
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

NCT05564117
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Costa Mesa, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

NCT01082640
View directory record Official record
Conditions
Renal Impairment
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Understanding Cognition, Oxytocin & Pain in Elders

NCT03878589
View directory record Official record
Conditions
Knee Osteoarthritis, Osteoarthritis
Interventions
Oxytocin (OT), Placebo (P)
Drug
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 28, 2026, 6:31 PM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

NCT07262268
View directory record Official record
Conditions
Familial Erythromelalgia
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 28, 2026, 6:31 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 28, 2026, 6:31 PM EDT
Withdrawn Not applicable Interventional

Olive Oil and Cardiovascular Health

NCT01983943
View directory record Official record
Conditions
Cardiovascular Disease, Endothelial Function
Interventions
Hydroxytyrosol, the active ingredient in olive oil., Placebo, Nutrition counseling, Endopat
Dietary Supplement · Behavioral · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

NCT02014376
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

NCT01738191
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
35 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 28, 2026, 6:31 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122 225 mg, BIIB122-Matching Placebo
Drug · Other
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 28, 2026, 6:31 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

NCT02340221
View directory record Official record
Conditions
Breast Cancer
Interventions
Taselisib, Placebo, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
16
States / cities
Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

NCT01121484
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained-release, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

NCT01772147
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 28, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00570778
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol/glycopyrrolate, indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 28, 2026, 6:31 PM EDT